Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.43 |
| ▸ | GSK3A | P49840 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | FLT4 | P35916 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15365948 | 0.84 | MAPT (0.39) | DYRK1AMAPK1MAPTATMTDP1 | |
| SCHEMBL18439916 | 0.80 | NPC1 (0.51) | MAPK1RPS6KA3SLC22A12MAPTFBP1 | |
| SCHEMBL2219704 | 0.78 | CYP2A6 (0.47) | MAPK1MAPTNPC1CYP1A2CYP3A4 | |
| SCHEMBL15325678 | 0.77 | MAPT (0.35) | MAPTRAB9A | |
| SCHEMBL2219698 | 0.77 | CSNK1D (0.47) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL23529991 | 0.75 | MAPT (0.42) | MAPK1MAPTFBP1TDP1NPC1 | |
| SCHEMBL15365950 | 0.74 | MAPT (0.36) | CDK2MAPK1MAPTATMTDP1 | |
| SCHEMBL2332272 | 0.74 | TDP1 (0.65) | MAPK1FBP1ATMTDP1EIF4E | |
| SCHEMBL29655008 | 0.72 | TDP1 (0.71) | MAPTFBP1ATMTDP1TAAR1 | |
| SCHEMBL721310 | 0.72 | TDP1 (0.71) | MAPTFBP1ATMTDP1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024914-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2022-01-27 | — | — | US | disclosed |
| WO-2021121420-A1 | BENZOPYRAZOLE COMPOUND AND INTERMEDIATE, PREPARATION METHOD, AND APPLICATION THEREOF | 江苏凯迪恩医药科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| US-10981909-B2 | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | SAMUMED, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210002273-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2021-01-07 | — | — | US | disclosed |
| US-10633380-B2 | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | SAMUMED, LLC (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190194187-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | MED-PATHWAYS II LIMITED (VG) | 2019-06-27 | — | — | US | disclosed |
| US-20170349584-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-12-07 | — | — | US | disclosed |
| WO-2017210407-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | SAMUMED, LLC (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170349584-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002273-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | WNT3A, WNT1, WNT3 | CSNK1D 164/4885GSK3A 16/4885GSK3B 11/4885 |
| US-10981909-B2 | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | WNT3A, WNT1, WNT3 | CSNK1D 164/4885GSK3A 16/4885GSK3B 11/4885 |
| US-20190194187-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | WNT3A, WNT1, WNT3 | CSNK1D 164/4885GSK3A 16/4885GSK3B 11/4885 |
| US-20170349584-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | WNT3A, WNT1, WNT3 | CSNK1D 164/4885GSK3A 16/4885GSK3B 11/4885 |
| US-20220024914-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | WNT3A, WNT1, WNT3 | CSNK1D 164/4885GSK3A 16/4885GSK3B 11/4885 |
| US-10633380-B2 | Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-C]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | WNT3A, WNT1, WNT3 | CSNK1D 164/4885GSK3A 16/4885GSK3B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.